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rhea, rectal bleeding, abdominal pain, fever, anemia, and loss 
of body weight.1 Several etiologies of this disease have been 
identified, but a complete cure is still difficult to achieve. There-
fore, a precise evaluation of disease activity is important for 
achieving better disease control. Recently, endoscopic find-
ings of the colonic mucosa have become essential in the eval-
uation of disease activity. The achievement of mucosal healing 
(MH) has been recommended as the goal for UC treatment, 
because it is associated with a reduced risk of relapse and col-
ectomy.2 However, a major disadvantage of using the mucosal 
status to evaluate disease activity is that it necessitates colo-
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Background/Aims: Fecal calprotectin (Fcal) as well as the fecal immunochemical test (FIT) are useful biomarkers for detect-
ing activity and mucosal healing in inflammatory bowel diseases. Here, we report the performance of simultaneous measure-
ments of Fcal and FIT for ulcerative colitis (UC) patients using the newly-developed latex agglutination turbidimetric immuno-
assay (LATIA) system. Methods: Fcal and hemoglobin were measured by the LATIA system in 152 UC patients who underwent 
colonoscopy. Fcal was also quantified with a conventional enzyme-linked immunosorbent assay (ELISA). Fecal markers were 
evaluated in conjunction with the mucosal status of UC, which was assessed via the Mayo endoscopic subscore (MES) clas-
sification. Results: The LATIA system could quantify calprotectin and hemoglobin simultaneously with the same fecal samples 
within 10 minutes. The values of the Fcal-LATIA closely correlated with those of the Fcal-ELISA (Spearman rank correlation 
coefficient, r=0.84; P<0.0001). The values of Fcal for each assay and the FIT all significantly correlated with the MESs (Spearman 
rank correlation coefficient, Fcal-LATIA: r=0.58, Fcal-ELISA: r=0.55, and FIT: r=0.72). The mucosal healing predictability (deter-
mined by an MES of 0 alone) of the Fcal-LATIA, Fcal-ELISA, and FIT-LATIA with the cutoffs determined by receiver operating 
characteristic curve analysis was 0.79, 0.78, and 0.92 for sensitivity, respectively, and 0.78, 0.69, and 0.73 for specificity, respec-
tively. Conclusions: The performance of the novel Fcal-LATIA was equivalent to that of the conventional Fcal assay. Simultane-
ous measurements with FITs would promote the clinical relevance of fecal biomarkers in UC. (Intest Res 2019;17:202-209 )
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INTRODUCTION
Ulcerative colitis (UC) is an idiopathic chronic inflammatory 
disorder that is characterized by manifestations such as diar-
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noscopy, which is an invasive and costly procedure. Thus, sur-
rogate markers that allow for the evaluation of the mucosal 
status have been sought after. 
Among several candidate markers, fecal calprotectin (Fcal) 
has become the front-runner, particularly in Western coun-
tries.3,4 Nevertheless, we have previously reported that a quan-
titative fecal immunochemical test (FIT) could predict the mu-
cosal status of UC to the same extent as or better than measur-
ing Fcal levels.5 Additionally, both fecal markers can predict 
the risk of relapse in quiescent UC patients.6 The cost and time 
benefits of FITs are superior to those of Fcal tests, while Fcal 
has been well-established for detecting changes in the muco-
sal inflammation of UC patients.7 Although it is desirable to 
weigh the 2 markers more precisely in terms of performance 
to estimate the mucosal status of UC, there are few assays that 
can measure both markers easily using a single sample. 
The latex agglutination turbidimetric immunoassay (LATIA) 
detects the amount of aggregation formed with latex-linked 
antibodies.8 Antigens are quantified by detecting the decrease 
in transmitted light via changes in absorbance (turbidity). FITs 
using the LATIA have the advantage of rapid and high-through-
put quantifications of hemoglobin in fecal samples with auto-
mated equipment.9 Moreover, the costs of LATIAs are lower 
than those of other methods, including ELISA. Therefore, this 
method has been used to screen for colorectal neoplasia in 
many countries.10-12 Recently, we have developed a break-
through assay that is able to measure levels of hemoglobin 
and calprotectin simultaneously using a single sampling probe 
with the LATIA system. The aim of the present study was to 
evaluate the performance of the novel Fcal assay (Fcal-LATIA) 
in predicting activity and MH of UC.
METHODS
1. Patients and Fecal Sampling
From March 2015 to September 2016, UC patients who were 
scheduled to undergo colonoscopy at the Okayama Universi-
ty Hospital were consecutively enrolled and requested to bring 
fecal samples for the measurement of Fcal and hemoglobin. 
All of the patients had an established diagnosis of UC accord-
ing to endoscopic and histologic assessments and had received 
adequate medical therapy.
Each patient prepared 2 fecal samples with 1 defecation; 1 
prepared in an OC-Auto sampling bottle 3 (Eiken Chemical, 
Tokyo, Japan) (Fig. 1A), and the other prepared in a TE-011 
sampling bottle (Sato Kasei Kogyosho Co. Ltd., Tochigi, Japan) 
(Fig. 1B). The former contained a special stabilizing buffer for 
the examination of the FIT and Fcal with the LATIA system, 
while the latter was an empty polypropylene tube with a spoon-
shaped probe. The patients traced or inserted the probe of the 
OC-Auto sampling bottle 3 at several different areas of the fe-
ces and then firmly placed it back into the tube to seal it. The 
patients also collected a specimen of feces using the TE-011 
sampling bottle. Fecal samples were collected within 2 days 
before colonoscopy and stored at room temperature until the 
day of colonoscopy. After submission, fecal samples for the 
LATIA analysis were stored at 4°C and examined within 3 weeks, 
because the fecal samples stored in the specific stabilizing 
buffer are stable for at least 3 days at room temperature and 3 
weeks at 4°C (Supplementary Fig. 1).13-15 Fecal samples for the 
ELISA analysis were stored at −70°C until they were shipped to 
a laboratory and were analyzed after approximately 40 sam-
Fig. 1. Fecal sampling bottles and OC-Sensor DIANA. (A) OC-Auto 
sampling bottle 3: the probe could be inserted or traced into dif-
ference areas of faces. (B) TE-011 sampling bottle: the probe 
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ples were collected. The measurement of FITs and Fcal were 
performed at the Biochemical Research Laboratory-I, Eiken 
Chemical Co., Ltd.
2. Measurement of Fcal and FITs
Fcal levels and FITs were simultaneously measured by means 
of the LATIA system for the fecal samples collected using the 
OC-Auto sampling bottle 3. The measurements were automat-
ically performed within 10 minutes after placing the sample 
bottles on the OC-Sensor DIANA (Eiken Chemical) (Fig. 1C).9 
Using this instrument, the Fcal levels were measured as fol-
lows: an aliquot of 20 μL of the fecal sample-containing buffer 
was pipetted into a cuvette and after approximately 15 sec-
onds, 100 μL of polystyrene latex particles coated with anti-
calprotectin mouse monoclonal antibodies and 100 μL of re-
action buffer were added. The absorbance of the samples at 
660 nm was measured after 30 and 390 seconds of incubation 
at 37°C and the changes in absorbance were calculated. The 
concentration of Fcal in the sample was determined on the 
basis of a calibration curve generated with a calprotectin cali-
brator. The measurement of FITs using the OC-Sensor DIANA 
has been reported previously.5-7,16,17 This system can accurately 
measure fecal hemoglobin at concentrations of 50–1,000 ng/
mL, and Fcal at concentrations of 20–2,000 µg/g. Fecal speci-
mens with a hemoglobin concentration of > 1,000 ng/mL or 
Fcal concentration of > 2,000 µg/g were measured following 
dilution. Since the measurement results of small amounts of 
Fcal ( < 20 µg/g) and fecal hemoglobin (< 50 ng/mL) may not 
be accurately measured in this system, the concentration val-
ues below the reliable ranges were regarded as the ranges’ min-
imum value (e.g., 20 µg/g for Fcal-LATIA or 50 ng/mL for FIT) 
in data handling.
Fcal levels were also determined with a conventional ELISA 
using the fecal samples collected from the TE-011 sampling 
bottle. The measurement was performed with a commercially 
available ELISA kit, the Phical® Calprotectin ELISA kit (Immun-
diagnostik, Germany) according to the manufacturer’s instruc-
tions. The quantitative range of calprotectin was between 0.65 
µg/g and 84,000 µg/g after the appropriate dilution of the fecal 
samples, ranging from 1:50 to 1:100,000 dilutions. The mea-
surement with the ELISA generally took more than 2 hours.
3. Endoscopic Assessment
Colonoscopies were performed after adequate bowel prepa-
ration, and observation until the caecum was achieved in all 
the patients. The mucosal status of UC patients was initially 
assessed by each endoscopist, via the Mayo endoscopic sub-
score (MES) classification,18 which ranges from a score of 0 to 
3 (severely active inflammation). In addition, stored still imag-
es were evaluated by at least 2 of the authors. A final consen-
sus was achieved following a discussion between the evalua-
tors and endoscopists. MES evaluations were performed at 
each portion of the colorectum (caecum and ascending colon 
combined, transverse colon, descending colon, sigmoid colon, 
and rectum), and the maximum values of the MESs were uti-
lized for analysis. MH was defined as an MES 0 alone or an 
MES of 0 or 1 throughout the colorectum. Endoscopists and 
evaluators were all blinded to the results of the fecal tests.
4. Statistical Analysis
Correlations between variables, including MESs, FITs, and 
Fcal, were estimated with Spearman rank order correlation 
coefficient. Receiver operating characteristic curves (ROC) 
were used to assess the best cutoff value for detecting MH. 
Sensitivity, specificity, positive predictive values (PPV), and 
negative predictive values (NPV) with a 95% CI for detecting 
MH were determined based on the Fcal and FIT results. All 
statistical analyses were performed using JMP pro version 12 
software (SAS Institute, Cary, NC, USA). All P-values were 2-sid-
ed and considered statistically significant when less than 0.05.
5. Ethical Considerations
All patients gave written informed consent to participate in 
this study. This study protocol conforms to the ethical guide-
lines of the 1975 Declaration of Helsinki and was approved by 
the Institutional Review Board of the Okayama University Grad-
uate School of Medicine, Dentistry, and Pharmaceutical Sci-
ences on February 24, 2015. Eiken Chemical provided the sam-




In total, 152 UC patients were enrolled (77 males [51%]; medi-
an age, 44 years [range, 14–78 years]; 101 [66%] had pancolitis, 
35 [23%] had left-side colitis, and 16 [11%] had proctitis; 113 
[74%] were in clinical remission and 39 [26%] were in the clini-
cally active stage of the disease) and submitted fecal samples 
for the measurement of Fcal and FITs. The median values of 
the Fcal-LATIA, Fcal-ELISA, and FIT results were 215 µg/g, 
155 µg/g, and 50 ng/mL, respectively (Table 1). 
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2.  Correlations between Colonoscopic Findings and 
Fcal-LATIA and Fcal-ELISA Results
The values of the assay results were evaluated in comparison 
with each other and in conjunction with the colonoscopic find-
ings. Each fecal marker significantly correlated with the colo-
noscopic findings evaluated with MESs (Spearman rank cor-
relation coefficient: Fcal-LATIA, r = 0.58, P < 0.0001; Fcal-ELI-
SA, r = 0.55, P < 0.0001; and FIT, r = 0.72, P < 0.0001) (Fig. 2). A 
significantly stronger correlation was observed between the 
Fcal-LATIA values and those of the Fcal-ELISA (Spearman 
rank correlation coefficient: r = 0.84, P < 0.0001) (Fig. 3).
Table 1. Characteristics of the Study Patients
Patient Value
Total             152
Age at onset (yr) 44 (14–78)
Duration of disease (mon) 129 (6–557)
Sex
   Male/female        77/75
Extent of disease
   Pancolitis/left-side/proctitis    101/35/16
Medication at colonoscopy
   Aminosalicylate 138 (91)
   Corticosteroids  7 (5)
   Mercaptopurine/azathioprine  74 (49)
   Tacrolimus  7 (5)
   Infliximab/adalimumab  28 (18)
Clinical activity
   Remission/active       113/39
Colonoscopy findings
   MES0/MES1/MES2/MES3   78/48/15/11
Fecal biomarkera
   Fecal calprotectin (LATIA, μg/g) 215 (53–970)
   Fecal calprotectin (ELISA, μg/g) 155 (47–549)
   Fecal hemoglobin concentrations (LATIA, ng/mL) 50 (50–437)
Values are presented as median (range) or number (%).
aMedian (interquartile range).
MES, Mayo endoscopic subscore; LATIA, latex agglutination turbidimetric 
immunoassay. 
Fig. 2. Correlations between fecal markers and colonoscopic findings (maximum MES in the colorectum). The results of the Fcal-LATIA 
(A), Fecal-ELISA (B), and FIT (C) were significantly correlated with the maximum MES (r=0.58, P<0.0001; r=0.55, P<0.0001; and r=0.72, 
P<0.0001; respectively). MES, Mayo endoscopic subscore; Fcal, fecal calprotectin; LATIA, latex agglutination turbidimetric immunoassay; 
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Fig. 3. Correlations between Fcal-LATIA and Fcal-ELISA results. A 
significantly close correlation was observed between the Fcal-LA-
TIA and Fcal-ELISA test results (r=0.84, P<0.0001). Y=1.40X+225.6, 
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3.  Sensitivity, Specificity, and Predictive Values of Fcal-
LATIA, Fcal-ELISA, and FIT-LATIA for Mucosal Healing
The predictability of MH, which was defined as an MES of 0 
alone or an MES of 0 or 1, was determined using the above-
mentioned fecal markers. When MH was defined as an MES 
of 0, the ROC analysis showed similar AUCs for the Fcal-LA-
TIA, Fcal-ELISA, and FIT (0.82, 0.80, and 0.83, respectively) 
(Fig. 4). The predictability using the cutoffs determined by the 
ROC analysis (224 µg/g for Fcal-LATIA, 184 µg/g for Fcal-ELI-
SA, and 50 ng/mL for FIT) revealed a sensitivity of 0.79, 0.78, 
and 0.92, respectively, and specificity of 0.78, 0.69, and 0.73, re-
spectively (Table 2). 
When MH was defined as an MES of 1, the ROC analysis 
showed similar AUCs between the Fcal-LATIA, Fcal-ELISA, 
and FIT (0.80, 0.78, and 0.90, respectively). The predictability 
using the cutoffs determined by the ROC analysis (251 µg/g 
for Fcal-LATIA, 204 µg/g for Fcal-ELISA, and 78 ng/mL for FIT) 
revealed a sensitivity of 0.63, 0.66, and 0.79, respectively, and 
specificity of 0.92, 0.85, and 0.96, respectively (Table 3). 
These results suggest that the performance of the Fcal-LA-
TIA was equivalent to that of the Fcal-ELISA in evaluating UC 
activity and that the sensitivity of FIT for MH was slightly high-
er than either Fcal test.
DISCUSSION
Although Fcal is an effective biomarker for IBD, long times for 
measurements and high costs have been critical problems lim-
iting its clinical use. A novel Fcal assay using the LATIA system 
can quantify Fcal within 10 minutes, and the values of the Fcal-
LATIA were significantly correlated with endoscopic activity in 
our study, including MH. In addition, the values with the new 
assay system closely correlated with those of a conventional 
Fcal assay using an ELISA. Moreover, it is noteworthy that the 
new system enabled the simultaneous measurement of Fcal 
and FITs, which would allow for the more precise prediction of 
the mucosal status and risk of relapse in UC patients.
The LATIA system was developed based on the antigen-an-
tibody immune response, and has been utilized for determin-
Table 2. Sensitivity, Specificity, and Predictive Values of Fecal 








Sensitivity 0.79 (0.71–0.88) 0.78 (0.69–0.87) 0.92 (0.86–0.98)
Specificity 0.78 (0.69–0.88) 0.69 (0.58–0.79) 0.73 (0.63–0.83)
PPV 0.79 (0.71–0.88) 0.73 (0.63–0.82) 0.78 (0.70–0.87)
NPV 0.78 (0.69–0.88) 0.75 (0.65–0.85) 0.90 (0.82–0.98)
Accuracy 0.79 (0.72–0.85) 0.74 (0.67–0.81) 0.83 (0.77–0.89)
Values in the parenthesis are 95% CI.
MES, Mayo endoscopic subscore; ROC, receiver operating characteristic 
curves; Fcal, fecal calprotectin; LATIA, latex agglutination turbidimetric 
immunoassay; FIT, fecal im munochemical test; PPV, positive predictive 
value; NPV, negative predictive value.
Table 3. Sensitivity, Specificity, and Predictive Values of Fecal Bio-
markers for Former Mucosal Healing (MES0 and MES1) with Opti-







Sensitivity 0.63 (0.54–0.71) 0.66 (0.58–0.74) 0.79 (0.71–0.86)
Specificity 0.92 (0.82–1.03) 0.85 (0.71–0.98) 0.96 (0.89–1.04)
PPV 0.98 (0.94–1.01) 0.95 (0.91–1.00) 0.99 (0.97–1.01)
NPV 0.34 (0.23–0.45) 0.34 (0.22–0.45) 0.48 (0.34–0.62)
Accuracy 0.68 (0.60–0.75) 0.69 (0.62–0.76) 0.82 (0.75–0.88)
Values in the parenthesis are 95% CI.
MES, Mayo endoscopic subscore; ROC, receiver operating characteristic 
curves; Fcal, fecal calprotectin; LATIA, latex agglutination turbidimetric 
immunoassay; FIT, fecal im munochemical test; PPV, positive predictive 
value; NPV, negative predictive value.
Fig. 4. Receiver operating characteristic curves of Fcal-LATIA, 
Fcal-ELISA, and FIT-LATIA for predicting mucosal healing. The re-
ceiver operating characteristic curves analysis for predicting mu-
cosal healing showed similar AUCs between the Fcal-LATIA, Fcal-
ELISA, and FIT (0.82, 0.80, and 0.83, respectively). Fcal, fecal cal-
protectin; LATIA, latex agglutination turbidimetric immunoassay; 
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ing clinical values of CRP,19 fibrinogen,20 and Helicobacter py-
lori antibodies21 in laboratories and hospitals. The system mea-
sures the aggregation of antigens and latex-linked antibodies. 
Antigens are quantified by detecting the decrease in transmit-
ted light indicated as changes in absorbance (turbidity). The 
principle of the LATIA is simple, and there are several advan-
tages to this assay system including rapidity, low costs, and no 
requirements for specialized equipment. At present, the cost 
of an Fcal-LATIA cannot be determined precisely because the 
kit is not yet commercially available. However, the system does 
not differ largely from FITs because the difference is only the 
addition of another kind of antibody. The cost of an FIT is $10, 
whereas that of an Fcal-ELISA is $30. Therefore, the cost of an 
Fcal-LATIA is expected to be lower than that of an Fcal-ELISA.
For the measurement of fecal samples using the LATIA sys-
tem, the specially designed sampling bottles showed 3 advan-
tages. Firstly, the collection of feces was easier than with the 
TE-011 sampling bottle. The specially designed bottle’s probe 
could be inserted or traced at different areas of feces, and these 
collection methods may minimize the biases caused by sample 
collection. In addition, the difference in fecal sampling might 
affect the commonly high values and high cutoffs associated 
with Fcal-LATIA because collection from a wide area of feces 
is likely to reflect the condition of the entire colorectum. Sec-
ondly, the bottle can be directly inserted into the dedicated 
automated equipment. Technicians need not open the bottle, 
keeping their hands clean, and, moreover, the time required 
for measurement is reduced. Finally, the fecal sample with the 
dedicated stabilizing buffer is stable for a few days at room tem-
perature and more than 3 weeks in the refrigerator (4°C).13-15 
This stability is convenient for patients submitting samples. 
Due to these advantages, FITs based on the LATIA system 
have been used to screen for colorectal neoplasia, not only in 
Japan, but also in Western countries in place of guaiac-based 
fecal occult blood tests. This system, however, has not been 
able to measure calprotectin concentrations due to the lack of 
adequate latex-linked antibodies. Herein, we described the 
development of a specific calprotectin antibody and measured 
calprotectin concentrations in feces with this system, to dem-
onstrate the suitability of the results for clinical use.
Fcal, a calcium-binding heterodimer that is abundant in the 
cytoplasm of neutrophils, is the most widely used surrogate 
marker of mucosal inflammation. According to a recent re-
view, Fcal has shown the ability to predict the presence of ac-
tive inflammation in UC patients with a sensitivity of 0.88 (95% 
CI, 0.84–0.92) and specificity of 0.79 (95% CI, 0.68–0.87) with 
cutoffs ranging from 48 to 280 μg/g.22 This fecal protein has 
also been used as a marker for MH, and the sensitivity and 
specificity for predicting MH have been reported to be 0.54–
0.91, and 0.72–0.85, respectively.5,23,24 
On the other hand, FITs have enabled the quantification of 
fecal hemoglobin concentrations using an antibody specific to 
human hemoglobin, and has proven to be an effective non-in-
vasive test for screening colorectal neoplasia.11 Ours is the first 
report on the usefulness of FITs in clinical practice for UC, and 
FITs can predict MH (MES 0) with a 92% to 95% sensitivity and 
62% to 71% specificity; the values of the present study are in 
line with our previous findings.5,6,7,16
There appear to be benefits to the simultaneous measure-
ment of Fcal and FITs in clinical practice for UC. Biomarkers 
for IBDs are mainly used clinically for the following purposes: 
monitoring disease activity, the prediction of MH, and the pre-
diction of the risk of relapses. We previously reported that FITs 
are superior in predicting MH, while Fcal is advantageous for 
monitoring endoscopic activity.7 Therefore, the simultaneous 
measurement of these 2 markers may compensate for each 
other’s shortcomings, and allow for the more precise predic-
tion of disease activity and MH.
More importantly, the simultaneous measurement of the 2 
markers may predict the risk of relapse in quiescent UC patients 
more effectively. As our previous reports have indicated, the cat-
egorization of patients into 3 groups according to fecal marker 
status (FIT-positive, FIT-negative and Fcal-positive, or both-neg-
ative) can efficiently stratify the risk of relapse into graded in-
creases of risk (FIT-negative and Fcal-positive: HR, 2.05; 95% CI, 
1.02–4.43; P = 0.0045, and FIT-positive: HR, 5.43; 95% CI, 2.57–
11.76; P < 0.0001, compared to both-negative).17 In the future, 
improvement of the clinical course of UC using the simultane-
ous measurement of both fecal markers should be verified.
In terms of the usefulness in clinical practice, the rapidity of 
the LATIA is a great advantage, because the evaluation of dis-
ease status and decision of treatment modification could be 
performed in 1 clinic/hospital visit without delay. In particular, 
the prediction of the risk of relapse might be invalid in situations 
with longer times for laboratory assay as in ELISA, because the 
results of fecal tests cannot be incorporated in clinical practice 
on the day of feces submission, and any delay could interfere 
with the early detection of the signs of relapse. In this context, 
the LATIA’s rapid measuring system would greatly influence the 
clinical practice of UC treatment, and many patients would 
benefit from an expectation of a better clinical course.
The results of several Fcal assays other than ELISA have been 
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reported, including methods using colloidal gold particles,25,26 
immunochromatography,27-30 and an enzyme fluoroimmuno-
assay.27 The correlation coefficients between these methods 
and a conventional ELISA for Fcal were 0.65 to 0.98, and the 
performance of these methods, with the exception of a fluoro-
immunoassay, was sufficiently similar to that of an ELISA. For 
these comparison studies, it should be noted that higher cor-
relations were observed when comparing fecal samples from 
the same sample tubes than when comparing separately col-
lected samples from different tubes (correlation coefficients: 
0.82–0.98 vs. 0.75–0.91, respectively).25-30 This suggests that the 
variations in the measurements of Fcal levels could be more 
attributable to biases due to sampling than due to assay meth-
ods. In this study, the sample tubes for the Fcal-LATIA were 
different from those for the Fcal-ELISA. Nonetheless, the cor-
relations between values from different sample tubes were 
sufficiently high (correlation coefficient: 0.84), indicating that 
the LATIA methods are reliable and merit clinical application. 
In this context, we verified the correlations between the Fcal-
LATIA and Fcal-ELISA using samples taken from the same 
sampling bottles (OC-Auto sampling bottle 3), with the results 
producing a higher correlation coefficient (0.95) than that of 
samples from different sampling bottles (Supplementary Fig. 
2), although the results of the ELISA tests with these samples 
were not validated.
There are limitations to this study. Firstly, the number of pa-
tients in the remission stage was relatively large. Validation 
studies with cohorts incorporating larger numbers of patients 
in the active disease stage are required. Secondly, as indicated 
above, the different sampling methods for feces required for 
the LATIA and ELISA tests probably affected the results.
In conclusion, Fcal measured with the novel LATIA system 
showed equivalent performance to a conventional ELISA sys-
tem in terms of monitoring endoscopic activity and the pre-
diction of MH in UC patients. Moreover, this new system en-
abled the simultaneous measurement of Fcal and FITs with 
one-time sampling. The clinical course of UC may be improved 
using this novel assay system for patient fecal samples. Future 
studies should verify the impact of simultaneous measurements 
on the clinical practice of IBD.
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Supplementary Fig. 2. The correlation between Fcal-LATIA and 
Fcal-ELISA (measured using the same sample from an OC-Auto 
sampling bottle). Y=1.27x+30.6, R2 =0.69. Fcal, fecal calprotectin; 




















Supplementary Fig. 1. The percentage of calprotectin recovery compared with the baseline over time at different temperatures (n=15). 
(A) The residual calprotectin recovery of specimens preserved in special buffer at 4°C for 21 days was 81% to 115%, average 97.3%, ex-
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